Skip to main content
NVDA+0.55%AAPL-1.15%GOOGL-1.29%MSFT-0.75%AMZN-1.79%TSM-1.08%SPCX-2.05%META+0.76%AVGO-0.71%TSLA+0.05%SKHY-0.08%BRK-B-0.02%LLY+0.40%MU+0.51%JPM-1.41%WMT-0.34%AMD+1.69%V-0.41%XOM+1.82%JNJ-1.15%ASMLa-1.17%0700.HK+1.90%MA-0.61%INTC+0.93%ABBV-0.08%1398.HK-2.09%CSCO+0.45%CVX+1.55%BAC-0.41%ORCL-1.11%COST-1.27%KO-1.01%DELL+3.11%CAT-0.73%HSBA.L-1.91%0005.HK-3.21%PG+0.21%UNH-1.67%LRCX-2.49%AP2d-2.39%AMAT-1.33%1816.HK-0.46%3988.HK-2.13%NFLX-2.63%GE-2.59%MS-2.63%0857.HK+0.60%HD-1.49%PM-0.16%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.93%CHFJPY+0.75%USDTHB+0.72%GBPJPY+0.67%GBPNZD+0.66%CADJPY+0.64%NZDCHF-0.62%NZDCAD-0.59%AUDUSD-0.58%EURUSD-0.49%EURJPY+0.47%EURNZD+0.45%AUDJPY+0.42%GBPTRY+0.41%NOKJPY+0.40%PLNJPY+0.38%AUDNZD+0.36%USDCAD+0.34%GBPHKD+0.32%USDCHF+0.31%NZDMXN-0.30%GBPMXN-0.28%GBPUSD-0.28%GBPAUD+0.28%SGDJPY+0.27%USDTRY+0.25%AUDCHF-0.25%AUDCAD-0.21%USDSEK+0.21%USDSGD+0.19%EURGBP-0.18%EURCAD-0.17%USDILS+0.16%EURCHF-0.16%EURSEK+0.15%EURSGD+0.14%CHFNOK-0.13%NZDSGD-0.13%EURCZK+0.12%EURAUD+0.10%GBPSGD+0.10%USDPLN+0.09%GBPZAR-0.09%AUDDKK-0.09%USDCNH+0.08%USDNOK+0.07%AUDNOK-0.07%GBPCAD+0.06%AUDSGD+0.06%NZDJPY+0.05%USDDKK+0.05%EURZAR-0.05%EURHKD-0.05%CADCHF-0.04%USDMXN+0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%GBPCHF+0.01%USDZAR+0.01%CHFSGD-0.01%EURNOK+0.01%EURDKK-0.01%CHFSEK0.00%EURCNH0.00%USOIL+2.68%UKOIL+1.78%W1+1.52%XNGUSD+1.30%SUGAR-1.10%COFFEE-1.01%C1+0.87%COCOA-0.86%S1+0.82%HG1+0.39%XAUUSD-0.38%GAUUSD-0.38%BTCUSD-2.79%ETHUSD-4.17%USDTUSD-0.03%XRPUSD-2.53%SOLUSD-3.46%TRXUSDT-0.44%ZECUSDT-4.31%DOGEUSD-2.41%XMRUSDT+0.57%LINKUSD-2.70%XLMUSD+0.08%BCHUSDT-1.61%UNIUSD-3.53%LTCUSD-2.81%HBARUSDT-0.52%TONUSD+26.79%SUIUSD-2.90%TAOUSDT-3.72%AAVEUSD-2.66%DOTUSDT-2.31%ICPUSDT-7.29%ONDOUSDT-3.74%WLDUSDT-1.82%ARBUSDT+3.88%ATOMUSDT-1.85%JUPUSDT-4.72%INJUSDT-10.07%STXUSDT-3.49%FETUSDT-4.47%PYTHUSDT-4.62%TIAUSDT-6.43%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-2.68%GRTUSDT-4.45%WIFUSDT-5.33%POLUSDT+0.01%IOTAUSDT-5.93%AXSUSDT-3.52%FARTCOINUSDT-2.30%EOSUSDT-4.57%DYDXUSDT-6.40%ORDIUSDT-2.31%GALAUSDT-2.06%NOTUSDT-0.18%RONINUSDT-11.07%NVDA+0.55%AAPL-1.15%GOOGL-1.29%MSFT-0.75%AMZN-1.79%TSM-1.08%SPCX-2.05%META+0.76%AVGO-0.71%TSLA+0.05%SKHY-0.08%BRK-B-0.02%LLY+0.40%MU+0.51%JPM-1.41%WMT-0.34%AMD+1.69%V-0.41%XOM+1.82%JNJ-1.15%ASMLa-1.17%0700.HK+1.90%MA-0.61%INTC+0.93%ABBV-0.08%1398.HK-2.09%CSCO+0.45%CVX+1.55%BAC-0.41%ORCL-1.11%COST-1.27%KO-1.01%DELL+3.11%CAT-0.73%HSBA.L-1.91%0005.HK-3.21%PG+0.21%UNH-1.67%LRCX-2.49%AP2d-2.39%AMAT-1.33%1816.HK-0.46%3988.HK-2.13%NFLX-2.63%GE-2.59%MS-2.63%0857.HK+0.60%HD-1.49%PM-0.16%0939.HK-2.83%USDJPY+0.98%NZDUSD-0.93%CHFJPY+0.75%USDTHB+0.72%GBPJPY+0.67%GBPNZD+0.66%CADJPY+0.64%NZDCHF-0.62%NZDCAD-0.59%AUDUSD-0.58%EURUSD-0.49%EURJPY+0.47%EURNZD+0.45%AUDJPY+0.42%GBPTRY+0.41%NOKJPY+0.40%PLNJPY+0.38%AUDNZD+0.36%USDCAD+0.34%GBPHKD+0.32%USDCHF+0.31%NZDMXN-0.30%GBPMXN-0.28%GBPUSD-0.28%GBPAUD+0.28%SGDJPY+0.27%USDTRY+0.25%AUDCHF-0.25%AUDCAD-0.21%USDSEK+0.21%USDSGD+0.19%EURGBP-0.18%EURCAD-0.17%USDILS+0.16%EURCHF-0.16%EURSEK+0.15%EURSGD+0.14%CHFNOK-0.13%NZDSGD-0.13%EURCZK+0.12%EURAUD+0.10%GBPSGD+0.10%USDPLN+0.09%GBPZAR-0.09%AUDDKK-0.09%USDCNH+0.08%USDNOK+0.07%AUDNOK-0.07%GBPCAD+0.06%AUDSGD+0.06%NZDJPY+0.05%USDDKK+0.05%EURZAR-0.05%EURHKD-0.05%CADCHF-0.04%USDMXN+0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%GBPCHF+0.01%USDZAR+0.01%CHFSGD-0.01%EURNOK+0.01%EURDKK-0.01%CHFSEK0.00%EURCNH0.00%USOIL+2.68%UKOIL+1.78%W1+1.52%XNGUSD+1.30%SUGAR-1.10%COFFEE-1.01%C1+0.87%COCOA-0.86%S1+0.82%HG1+0.39%XAUUSD-0.38%GAUUSD-0.38%BTCUSD-2.79%ETHUSD-4.17%USDTUSD-0.03%XRPUSD-2.53%SOLUSD-3.46%TRXUSDT-0.44%ZECUSDT-4.31%DOGEUSD-2.41%XMRUSDT+0.57%LINKUSD-2.70%XLMUSD+0.08%BCHUSDT-1.61%UNIUSD-3.53%LTCUSD-2.81%HBARUSDT-0.52%TONUSD+26.79%SUIUSD-2.90%TAOUSDT-3.72%AAVEUSD-2.66%DOTUSDT-2.31%ICPUSDT-7.29%ONDOUSDT-3.74%WLDUSDT-1.82%ARBUSDT+3.88%ATOMUSDT-1.85%JUPUSDT-4.72%INJUSDT-10.07%STXUSDT-3.49%FETUSDT-4.47%PYTHUSDT-4.62%TIAUSDT-6.43%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-2.68%GRTUSDT-4.45%WIFUSDT-5.33%POLUSDT+0.01%IOTAUSDT-5.93%AXSUSDT-3.52%FARTCOINUSDT-2.30%EOSUSDT-4.57%DYDXUSDT-6.40%ORDIUSDT-2.31%GALAUSDT-2.06%NOTUSDT-0.18%RONINUSDT-11.07%
CP

Collegium Pharmaceutical, Inc. (COLL)

NASDAQ • Healthcare

$22.81
+$0.05 (+0.3%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$22.8
Previous Close$22.81
Day Range$22.5 - $23.19
Avg. Volume (3M)847.8K
Market Cap$724.7M
P/E Ratio14.9
52 Week Range
$22.5$50.79
Next EarningsIn 51 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$199.8M100%
Gross Profitminus cost of goods$110.2M55%
Operating Incomeminus R&D and overhead$3.6M2%

In plain terms: out of every $100 in revenue, Collegium Pharmaceutical, Inc. currently loses $8.

Fundamentals & Financials

Revenue (TTM)
$808.2M
Net Income (TTM)
$47.9M
EPS (TTM)
$1.53
ROA (TTM)
2.24%
Current Ratio
1.03
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-4.7%Q1 2026$2.04
+15.8%Q2 2026$1.76
+11.6%Q3 2026$1.92
Next

Nov 5

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +11.6%

Collegium Pharmaceutical’s adjusted EPS topped expectations while revenue came in line in the second fiscal quarter of 2026, based on preliminary results reported August 6, 2026. Revenue rose 6.3% to about $200.0 million (up from $188.0 million a year ago), with the consensus comparison showing revenue of $199.9 million in line with the $199.6 million estimate (+0.1%). On the bottom line, adjusted EPS of $1.92 topped the $1.72 estimate (+11.6%) and was up from $1.68 a year ago (+14.3%). Profitability held at a gross margin of roughly 55%, as gross profit reached about $110.3 million. The quarter also generated operating cash flow of about $71.3 million. For the next period, consensus calls for EPS of $1.86 on revenue of $218.5 million.

View full earnings history

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. develops and markets prescription pain medicines in the healthcare sector, focused on specialty branded opioids and related therapies. Listed on the NASDAQ as COLL, the company generated $780.6 million of revenue in FY2025 and operates within specialty and generic drug manufacturing.

Name
Collegium Pharmaceutical, Inc.
CEO
Vikram Karnani
Website
www.collegiumpharma.com
Industry
Healthcare
Year Founded
2002
Employees
423

Today's Snapshot

AI-generated

COLL started the session slightly lower at 22.74, while its sector was flat. COLL is trading within 0.3% of its 52-week low of 22.26.

Trading Volume

Below 10d avg (868.5K)

98.7K

vs S&P 500 Today

Underperforming Market

-1.74%

Updated: September 15, 2026 at 15:02 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
Coll is trading around 22.31 and shows broad bearish control as price sits well below both short- and long-term moving averages while pivot levels remain marginally above the market. Momentum indicators are deeply oversold by oscillators even as some register short-term buy signals, but MACD remains negative and volume-based OBV is signaling distribution. Trend strength is notable, with ADX reflecting a strong directional move, and volatility is elevated relative to price, which underscores the downside pressure. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$23.51 - $35.36
    Sell
  • RSI (14)21.20
    Buy
  • Stochastic %K (14, 3, 3)2.81
    Buy
  • MACD Level (12, 26)-2.15
    Neutral

Peers & Related Assets

PLSEPulse Biosciences, Inc.
$54.21+2.1%
INVAInnoviva, Inc.
$20.9+1.2%
CRONCronos Group Inc.
$3.17-2.2%
AMPHAmphastar Pharmaceuticals, Inc.
$23.91+0.6%
PCRXPacira BioSciences, Inc.
$24.68-2.7%
MDXGMiMedx Group, Inc.
$4.64+1.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.